Intangible assets and goodwill |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets and goodwill [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets and goodwill |
4. Intangible assets and goodwill
Individual IPR&D
projects and goodwill are tested for impairment on an annual basis in the
fourth quarter, and in between annual tests if an event occurs or circumstances
change that would more likely than not reduce the fair value of each technology
or the Company’s reporting unit below its carrying value. In April 2026, the
Company received a CRL from the FDA in response to the Company’s NDA submission
for GTx-104, triggering a comprehensive review of the Company’s individual
IPR&D projects and goodwill as of June 30, 2026. In June 2026, following
continued evaluation of strategic priorities and focus on GTx-104, the Company impaired the $13,533 capitalized carrying
value of GTx-102 and GTx-101 which is recorded within operating expenses in the
condensed consolidated statements of loss and comprehensive loss for the three
months ended June 30, 2026. The impairment
assessments resulted in the following activity during the three months ended
June 30, 2026:
As of June 30, 2026, the estimated fair value of GTx-104 was not less than its carrying value, and no impairment was recorded.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||